These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 33990390)

  • 1. Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19.
    Mohsenian Naghani S; Jansen MM; Jaspers T; Bastiaans D; Burger D
    Eur J Hosp Pharm; 2023 Mar; 30(e1):e106-e108. PubMed ID: 33990390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
    Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
    Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
    Kashuba AD; Tierney C; Downey GF; Acosta EP; Vergis EN; Klingman K; Mellors JW; Eshleman SH; Scott TR; Collier AC
    AIDS; 2005 Jan; 19(2):145-52. PubMed ID: 15668539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
    Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
    Simpson KN; Pei PP; Möller J; Baran RW; Dietz B; Woodward W; Migliaccio-Walle K; Caro JJ
    Pharmacoeconomics; 2013 May; 31(5):427-44. PubMed ID: 23620210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.
    Wire MB; McLean HB; Pendry C; Theodore D; Park JW; Peng B
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2846-51. PubMed ID: 22391553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
    Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
    J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients.
    Wang K; D'Argenio DZ; Acosta EP; Sheth AN; Delille C; Lennox JL; Kerstner-Wood C; Ofotokun I
    Clin Pharmacokinet; 2014 Apr; 53(4):361-71. PubMed ID: 24311282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
    Simpson KN; Jones WJ; Rajagopalan R; Dietz B
    Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19.
    Batteux B; Bodeau S; Gras-Champel V; Liabeuf S; Lanoix JP; Schmit JL; Andréjak C; Zerbib Y; Haye G; Masmoudi K; Lemaire-Hurtel AS; Bennis Y
    Br J Clin Pharmacol; 2021 Mar; 87(3):1547-1553. PubMed ID: 32692462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.
    Karolyi M; Pawelka E; Mader T; Omid S; Kelani H; Ely S; Jilma B; Baumgartner S; Laferl H; Ott C; Traugott M; Turner M; Seitz T; Wenisch C; Zoufaly A
    Wien Klin Wochenschr; 2021 Apr; 133(7-8):284-291. PubMed ID: 32776298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients.
    Ramautarsing RA; van der Lugt J; Gorowara M; Sophonphan J; Ananworanich J; Lange JM; Burger DM; Phanuphak P; Ruxthungtham K; Avihingsanon A
    Antivir Ther; 2013; 18(2):249-52. PubMed ID: 22908131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study.
    Luque AE; Cohn SE; Park JG; Cramer Y; Weinberg A; Livingston E; Klingman KL; Aweeka F; Watts DH
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2094-101. PubMed ID: 25624326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
    Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H
    PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.
    Bastiaans DE; Forcat S; Lyall H; Cressey TR; Hansudewechakul R; Kanjanavanit S; Noguera-Julian A; Königs C; Inshaw JR; Chalermpantmetagul S; Saïdi Y; Compagnucci A; Harper LM; Giaquinto C; Colbers AP; Burger DM;
    Pediatr Infect Dis J; 2014 Mar; 33(3):301-5. PubMed ID: 24356253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.
    Ouedraogo HG; Matteelli A; Sulis G; Compaore TR; Diagbouga S; Tiendrebeogo S; Roggi A; Cisse K; Giorgetti PF; Villani P; Sangare L; Simpore J; Regazzi M; Kouanda S
    Ann Clin Microbiol Antimicrob; 2020 Jan; 19(1):3. PubMed ID: 31969147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection.
    Alexander CS; Montaner JS; Asselin JJ; Ting L; McNabb K; Harris M; Guillemi S; Harrigan PR
    Ther Drug Monit; 2004 Oct; 26(5):516-23. PubMed ID: 15385834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.
    Hassaniazad M; Farshidi H; Gharibzadeh A; Bazram A; Khalili E; Noormandi A; Fathalipour M
    J Med Virol; 2022 Jul; 94(7):3184-3191. PubMed ID: 35292989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.